Checkmate Pharmaceuticals Inc. (CMPI): Price and Financial Metrics


Checkmate Pharmaceuticals Inc. (CMPI): $4.27

-0.12 (-2.73%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CMPI Stock Price Chart Interactive Chart >

Price chart for CMPI

CMPI Price/Volume Stats

Current price $4.27 52-week high $23.10
Prev. close $4.39 52-week low $4.19
Day low $4.19 Volume 38,573
Day high $4.59 Avg. volume 47,334
50-day MA $5.19 Dividend yield N/A
200-day MA $9.42 Market Cap 92.34M

Checkmate Pharmaceuticals Inc. (CMPI) Company Bio


Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. It specializes in the field of CpG oligonucleotides. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.


CMPI Latest News Stream


Event/Time News Detail
Loading, please wait...

CMPI Latest Social Stream


Loading social stream, please wait...

View Full CMPI Social Stream

Latest CMPI News From Around the Web

Below are the latest news stories about Checkmate Pharmaceuticals Inc that investors may wish to consider to help them evaluate CMPI as an investment opportunity.

Checkmate Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO, will present at the Cantor Virtual Global Healthcare Conference on Thursday, September 30 from 10:40-11:10am ET. Checkmate will also host 1x1 investor meetings during the conference.

Intrado Digital Media | September 14, 2021

Checkmate Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The pre-recorded webcast will be available on demand, starting on Monday, September 13, 2021 at 7:00am ET. Checkmate will also host 1x1 investor meetings during the conference.

Intrado Digital Media | September 7, 2021

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV ) Alkermes plc (NASDAQ: ALKS ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Gilead Sciences, Inc. (NASDAQ: GILD ) GlaxoSmithKline plc (NYSE: GSK ) ( announced FDA approval for label expansion for its Jemperli) Novo Nordisk A/S (NYSE: NVO ) Innoviva, Inc. (NASDAQ: INVA ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI ) Omega Therapeutics, Inc. (NASDAQ: OMGA ) (IPOed July 30) Pfizer, Inc. (NYSE: PFE ) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) ResMed Inc. (NYSE: RMD ) TScan Therapeutics, Inc. (NASDAQ: TCRX ) Virpax Pharmaceutical...

Benzinga | August 19, 2021

Checkmate Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update

Clinical trial programs for vidutolimod (CMP-001) in melanoma and head and neck cancer indications ongoing

Intrado Digital Media | August 12, 2021

Checkmate Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Checkmate Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

Business Wire | August 2, 2021

Read More 'CMPI' Stories Here

CMPI Price Returns

1-mo -14.94%
3-mo -32.54%
6-mo -65.14%
1-year -55.29%
3-year N/A
5-year N/A
YTD -70.73%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8109 seconds.